Incretins, a Fragment, and a Mitochondrial Signal: Metabolic Peptides Under Study

The short version

metabolixpeptides is a reading desk, not a store. It collects what the published research literature says about three peptides that touch metabolic regulation — how the body manages appetite, blood sugar, and energy — from three very different directions.

Semaglutide is an approved prescription medicine that mimics a gut hormone called GLP-1 (short for glucagon-like peptide-1), and it carries the deepest, most rigorous evidence base of the three: large trials in diabetes, weight loss, heart disease, and kidney disease. AOD-9604 is a small fragment cut from the tail end of human growth hormone, built to keep its fat-metabolizing activity without the growth-promoting side effects — a promising idea in mice that did not hold up in its own human obesity trial. MOTS-c is different again: not a hormone at all, but a tiny peptide your own mitochondria — the energy-generating structures inside your cells — already make, now being studied in animals for its effect on blood sugar and muscle.

These three sit at very different points on the evidence ladder, and every page here says so plainly. Nothing on this site is for sale, and no page recommends a dose to any person.

The metabolic signaling map

Three compounds, three different signaling layers — that is the organizing idea behind this desk. Read together, they sketch a rough map of how researchers currently think about metabolic control at three different scales.

At the receptor level, semaglutide works the way the body's own after-meal hormones do: it binds a cell-surface receptor (GLP-1R) and changes how much insulin is released, how fast the stomach empties, and how hungry the brain says the body is. At the tissue level, AOD-9604 was designed to isolate a single activity buried inside a much larger, more complicated hormone — growth hormone's fat-metabolizing tail — and deliver it without triggering the rest of what growth hormone does. At the cellular level, MOTS-c operates from inside the mitochondrion itself, the structure that turns food into usable energy, and appears able to travel to the cell nucleus and change which genes get switched on under metabolic stress ^[15].

MOTS-c leads this desk not because its evidence is the strongest — it is, in fact, the least clinically tested of the three — but because it represents the newest and structurally most distinct layer of the map: a signal generated by the mitochondria themselves rather than one delivered to a receptor from outside the cell.

What are research peptides?

Peptides are short chains of amino acids, the same building blocks that make up proteins, just far smaller. All three peptides on this desk are technically peptides in that sense, but they occupy very different regulatory and evidentiary positions.

Semaglutide is a synthetic analogue of a natural human hormone, chemically modified for a longer half-life, and it has gone through the full arc of drug development: laboratory characterization, animal studies, and multiple large human clinical trial programs, ending in FDA approval for several indications ^[4][3]. AOD-9604 followed the same arc partway — it reached Phase IIb human obesity trials — but its development program was discontinued after that trial failed to demonstrate significant weight loss over placebo ^[8]. MOTS-c has not yet reached that stage at all: everything published about its effect on metabolism, exercise performance, or aging comes from cell and animal studies, and it is sold, where it is sold, strictly as a research chemical, not a medicine ^[16].

How this desk reads the literature

Each peptide page on this site summarizes its published studies, cites them by number, and links to one shared references list that aggregates every source across all three compounds. Where a claim comes from a large randomized trial, the page says so; where it comes from a mouse study, a small human cohort, or a pharmacovigilance database rather than a controlled trial, the page says that too — the strength of a finding is part of what this desk reports, not an afterthought.

Where a page describes what people say about their own experience with a compound, in patient forums or peptide-research communities, that material is always labeled clearly as anecdotal — a report of what is said, not a clinical finding — and it never comes attached to a dose. Read alongside the cited literature, the two layers are meant to give an honest, calibrated picture: not just what was studied, but what people report living with day to day, and how confidently each layer of that picture can be trusted.